News & Updates

The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.

In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.

For individuals with obesity who are scheduled to undergo bariatric surgery, faecal microbiota transplantation (FMT) from a lean donor does not appear to help reduce weight before or after the procedure, according to a study.

In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.

Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).

Researchers at the Chinese University of Hong Kong (CUHK) are recruiting pregnant women with inflammatory bowel disease (IBD), their newborns and spouse for a study to investigate how early-life exposure influences gut microbiota and IBD risk in the offspring, and to develop novel treatments for the increasingly prevalent condition.